SAO PAULO (Reuters) – Brazilian company Precisa Medicamentos, representing India’s Bharat Biotech, on Monday said it requested that the country’s health regulator, Anvisa, grant emergency authorization to use the Covaxin COVID-19 vaccine.
In addition, it said Covaxin would be trialed in a Phase Three study in Brazil carried out in partnership with Sao Paulo’s Albert Einstein hospital.
(Reporting by Marcelo Rochabrun; Editing by Leslie Adler)
Man City beats Brighton 4-0 to stay on course for another Premier League title. Phil Foden scores 2
Giants select Malik Nabers with 6th pick at 2024 NFL Draft
The NFL draft gives players a chance to flaunt their style on the red carpet
Suns’ Big 3 in a big pickle, down 2-0 against the Timberwolves as series moves to Phoenix
Roger Goodell envisions more overseas games, more streaming and more cities hosting the NFL draft
Guatemalan prosecutors raid offices of Save the Children charity
First with Trump, now with Kamala Harris: Kim Kardashian is advocating for criminal justice reform
USC’s move to cancel commencement amid protests draws criticism from students, alumni
Key moments from landmark Supreme Court arguments on Trump’s immunity claims
Google parent reports another quarter of robust growth, rolls out first-ever quarterly dividend
17 states challenge federal rules entitling workers to accommodations for abortion
New York City to require warning labels for sugary foods and drinks in chain restaurants
Selling weight-loss and muscle-building supplements to minors in New York is now illegal
Minneapolis smokers to pay some of the highest cigarette prices in US with a $15 per-pack minimum
